Clostridium difficile infections in solid organ transplantation

American Journal of Transplantation

Volumn 13, Issue SUPPL.4, 2013, Pages 42-49

  Dubberke, E R ^a   Burdette, S D ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WRIGHT STATE UNIVERSITY   (United States)

Author keywords

Antibiotic associated diarrhea; Clostridium difficile; nosocomial infection; pseudomembranous colitis; solid organ transplant

Indexed keywords

FIDAXOMICIN; IMMUNOGLOBULIN; METRONIDAZOLE; VANCOMYCIN;

ABDOMINAL PAIN; ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CYTOTOXICITY TEST; DIARRHEA; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EXPOSURE; FEVER; HUMAN; HYPOALBUMINEMIA; ILEOSTOMY; INCIDENCE; INFECTION CONTROL; INFECTIOUS DISEASE ELISA KIT; LEUKOCYTOSIS; NUCLEIC ACID AMPLIFICATION; ORGAN TRANSPLANTATION; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SOLID ORGAN TRANSPLANTATION;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; INFECTION CONTROL; ORGAN TRANSPLANTATION; RISK FACTORS;

EID: 84874840254     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12097     Document Type: Article

References (42)

1. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-455.
2. Nomura K, Fujimoto Y, Yamashita M, et al. Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. Scand J Gastroenterol 2009; 44: 74-78.
3. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365: 1693-1703.
4. Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN,. Acquisition of Clostridium difficile by hospitalized patients: Evidence for colonized new admissions as a source of infection. J Infect Dis 1992; 166: 561-567.
5. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442-2449.
6. Boutros M, Al Shaibi M, Chan G, et al. Clostridium difficile colitis: Increasing incidence, risk factors, and outcomes in solid organ transplant recipients. Transplantation 2012; 93: 1051-1057.
7. Riddle DJ, Dubberke ER,. Clostridium difficile infection in solid organ transplant recipients. Curr Opin Organ Transplant 2008; 13: 592-600.
8. Zerey M, Paton BL, Lincourt AE, Gersin KS, Kercher KW, Heniford BT,. The burden of Clostridium difficile in surgical patients in the United States. Surg Infect 2007; 8: 557-566.
9. Dubberke ER, Butler AM, Yokoe DS, et al. Multicenter study of Clostridium difficile infection rates from 2000 to 2006. Infect Control Hosp Epidemiol 2010; 31: 1030-1037.
10. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: An underappreciated and increasing cause of death and complications. Ann Surg 2002; 235: 363-372.
11. Bignardi GE,. Risk factors for Clostridium difficile infection. J Hosp Infect 1998; 40: 1-15.
12. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN,. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998; 351: 633-636.
13. Kyne L, Warny M, Qamar A, Kelly CP,. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342: 390-397.
14. Munoz P, Giannella M, Alcala L, et al. Clostridium difficile associated diarrhea in heart transplant recipients: Is hypogammaglobulinemia the answer? J Heart Lung Transplant 2007; 26: 907-914.
15. Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ,. Clostridium difficile-associated disease in a setting of endemicity: Identification of novel risk factors. Clin Infect Dis 2007; 45: 1543-1549.
16. Dubberke ER, Han Z, Bobo L, et al. Impact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections. J Clin Microbiol 2011; 49: 2887-2893.
17. Schmidt ML, Gilligan PH,. Clostridium difficile testing algorithms: What is practical and feasible? Anaerobe 2009; 15: 270-273.
18. Mohan SS, McDermott BP, Parchuri S, Cunha BA,. Lack of value of repeat stool testing for Clostridium difficile toxin. Am J Med 2006; 119: 356-358.
19. Chapin KC, Dickenson RA, Wu F, Andrea SB,. Comparison of five assays for detection of Clostridium difficile toxin. J Mol Diagn 2011; 13: 395-400.
20. Kvach EJ, Ferguson D, Riska PF, Landry ML,. Comparison of BD geneOhm Cdiff real-time PCR assay with a two-step algorithm and a toxin A/B enzyme-linked immunosorbent assay for diagnosis of toxigenic Clostridium difficile infection. J Clin Microbiol 2010; 48: 109-114.
21. Sloan LM, Duresko BJ, Gustafson DR, Rosenblatt JE,. Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. J Clin Microbiol 2008; 46: 1996-2001.
22. Johnson S, Peterson LR, Gerding DN,. Intravenous metronidazole and Clostridium difficile-associated diarrhea or colitis. J Infect Dis 1989; 160: 1087-1088.
23. Sethi AK, Al Nassir WN, Nerandzic MM, Donskey CJ,. Skin and environmental contamination with vancomycin-resistant Enterococci in patients receiving oral metronidazole or oral vancomycin treatment for Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2009; 30: 13-17.
24. Scheinfeld N, Biggers K,. Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea. Curr Opin Investig Drugs 2008; 9: 913-924.
25. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB,. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-307.
26. Fekety R, Silva J, Kauffman C, Buggy B, Deery HG,. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: Comparison of two dosage regimens. Am J Med 1989; 86: 15-19.
27. Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN,. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007; 51: 2716-2719.
28. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12: 281-289.
29. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-431.
30. Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011; 53: 440-447.
31. Apisarnthanarak A, Khoury H, Reinus WR, Crippin JS, Mundy LM,. Severe Clostridium difficile colitis: The role of intracolonic vancomycin? Am J Med 2002; 112: 328-329.
32. Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS,. Diverting loop ileostomy and colonic lavage: An alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 2011; 254: 423-427.
33. Byrn JC, Maun DC, Gingold DS, Baril DT, Ozao JJ, Divino CM,. Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg 2008; 143: 150-154.
34. Juang P, Skledar SJ, Zgheib NK, et al. Clinical outcomes of intravenous immune globulin in severe Clostridium difficile associated diarrhea. Am J Infect Control 2007; 35: 131-137.
35. Kalima P, Masterton RG, Roddie PH, Thomas AE,. Lactobacillus rhamnosus infection in a child following bone marrow transplant. J Infect 1996; 32: 165-167.
36. Curry SR, Marsh JW, Shutt KA, et al. High frequency of Rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009; 48: 425-429.
37. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN,. Interruption of recurrent Clostridium difficile associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007; 44: 846-848.
38. Dubberke ER, Gerding DN, Classen D, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29 (Suppl 1): S81-S92.
39. Valiquette L, Cossette B, Garant MP, Diab H, Pepin J,. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007; 45 (Suppl 2): S112-S121.
40. Davey P, Brown E, Fenelon L, et al. Systematic review of antimicrobial drug prescribing in hospitals. Emerg Infect Dis 2006; 12: 211-216.
41. Gerding DN, Muto CA, Owens RC, Jr,. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 2008; 46 (Suppl 1): S43-S49.
42. Oughton MT, Loo VG, Dendukuri N, Fenn S, Libman MD,. Hand hygiene with soap and water is superior to alcohol rub and antiseptic wipes for removal of Clostridium difficile. Infect Control Hosp Epidemiol 2009; 30: 939-944.